Recent Updates
Recently added Catalysts
GERN Negative Sentiment

GERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Geron Corporation and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against Geron Corporation, targeting investors who purchased securities between February 28, 2024, and February 25, 2025. The complaint accuses the company of providing misleading information about the expected growth and market potential of Rytelo while downplaying associated risks. Investors are encouraged to contact the law firm for participation in the case. The deadline for applying as a lead plaintiff in the lawsuit is May 12, 2025.
Price reaction · baseline $1.7 (2025-03-19 close) · hit after-hours · 1 other GERN headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Geron Corporation.
  • Allegations include misleading statements regarding Rytelo's market potential and related risks.
  • Investors may face losses due to the lawsuit's implications on Geron's reputation and share value.
  • The lawsuit highlights concerns about competition and monitoring requirements affecting sales.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
4.4%
average across 4 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
Imetelstat
Phase 3 · Myelofibrosis

Full Press Release Details

NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”). Investors have until May 12, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that throughout the Class Period, Defendants provided investors with material information concerning Defendants' expectations for the launch and growth potential of Rytelo (imetelstat). The Complaint alleges that Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales.
If you purchased or otherwise acquired Geron shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the class action lawsuit against Geron Corporation about?

The lawsuit accuses Geron of misleading investors about Rytelo's market potential.

What is the deadline to apply as lead plaintiff in the lawsuit?

Investors must apply by May 12, 2025, to be considered as lead plaintiff.

Who can join the class action lawsuit?

Any individual or entity that purchased Geron securities during the Class Period.

How can I contact Bragar Eagel & Squire for more information?

You can email investigations@bespc.com or call (212) 355-4648.

What does Bragar Eagel & Squire, P.C. specialize in?

The firm specializes in commercial and securities litigation for investors.

Last updated: Mar 20, 2025